Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDF
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. 1-butyl-2-(hydroxylmethyl)piperidine-3,4,5-triol
2. 1-deoxy-galactonojirimycin
3. 1-deoxygalacto-nojirimycin
4. 1-deoxygalactonojirimycin
5. At1001 Deoxyjirimycin
6. Galafold
7. Gr181413a
8. Lucerastat
9. Migalastat
10. Migalastat Hcl
11. N-butyldeoxygalacto-nojirimycin
12. N-butyldeoxygalactonojirimycin
13. Nb-dgj
1. Migalastat Hcl
2. 75172-81-5
3. Deoxygalactonojirimycin Hydrochloride
4. Galafold
5. 1-deoxygalactonojirimycin Hydrochloride
6. Amigal
7. Migalastat Hydrochloride [usan]
8. Migalastat (hydrochloride)
9. Cly7m0xd20
10. 75172-81-5 (hcl)
11. At-1001 (migalastat Hydrochloride)
12. (2r,3s,4r,5s)-2-(hydroxymethyl)piperidine-3,4,5-triol Hydrochloride
13. (2r,3s,4r,5s)-2-(hydroxymethyl)piperidine-3,4,5-triol Hydrochloride.
14. Gr181413a
15. Unii-cly7m0xd20
16. Migalastathcl
17. Galafold (tn)
18. Deoxygalactonojirimycin,hydrochloride
19. Deoxygalactonojirimycin, Hydrochloride
20. 1-deoxygalactonojirimycin Hcl
21. Schembl3802618
22. Chembl2107355
23. Dtxsid801026249
24. (+)-migalastat Hydrochloride
25. Hy-14929a
26. Mfcd00269962
27. Migalastat Hydrochloride (jan/usan)
28. Migalastat Hydrochloride [mi]
29. Migalastat Hydrochloride [jan]
30. 3,4,5-piperidinetriol, 2-(hydroxymethyl)-, Hydrochloride, (2r,3s,4r,5s)-
31. At13690
32. Cs-6380
33. Migalastat Hydrochloride [who-dd]
34. Migalastat Hydrochloride [orange Book]
35. D05031
36. 1,5-dideoxy-1,5-imino-d-galactitol Hydrochloride
37. W-203722
38. Q27275527
39. (+)-(2r,3s,4r,5s)-2-(hydroxymethyl)piperidine-3,4,5-triol Hydrochloride
40. (2r,3s,4r,5s)-2-(hydroxymethyl)-3,4,5-piperidinetriol Hydrochloride
41. (2r,3s,4r,5s)-2-(hydroxymethyl)piperidine-3,4,5-triol;hydrochloride
42. 3,4,5-piperidinetriol, 2-(hydroxymethyl)-, Hydrochloride (1:1), (2r,3s,4r,5s)-
43. 3,4,5-piperidinetriol, 2-(hydroxymethyl)-, Hydrochloride,[2r-(2a,3a,4a,5b)]-
Molecular Weight | 199.63 g/mol |
---|---|
Molecular Formula | C6H14ClNO4 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 1 |
Exact Mass | 199.0611356 g/mol |
Monoisotopic Mass | 199.0611356 g/mol |
Topological Polar Surface Area | 93 Ų |
Heavy Atom Count | 12 |
Formal Charge | 0 |
Complexity | 132 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Galafold is indicated for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (-galactosidase A deficiency) and who have an amenable mutation.
A16AX
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37632
Submission : 2023-02-26
Status : Active
Type : II
NDC Package Code : 42765-051
Start Marketing Date : 2023-01-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Date of Issue : 2022-06-03
Valid Till : 2025-05-25
Written Confirmation Number : WC-0002A3
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-04-08
Pay. Date : 2022-02-25
DMF Number : 36827
Submission : 2022-02-25
Status : Active
Type : II
NDC Package Code : 59651-662
Start Marketing Date : 2024-01-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-03-17
Pay. Date : 2021-12-15
DMF Number : 36618
Submission : 2022-02-28
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38135
Submission : 2023-03-25
Status : Active
Type : II
NDC Package Code : 14501-0115
Start Marketing Date : 2023-03-25
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-06-09
Pay. Date : 2022-05-26
DMF Number : 36729
Submission : 2022-03-31
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info : RX
Registration Country : USA
Brand Name : GALAFOLD
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 123MG BASE
Packaging :
Approval Date : 2018-08-10
Application Number : 208623
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : Switzerland
Brand Name : Galafold
Dosage Form : Kaps
Dosage Strength : 123mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Canada
MIGALASTAT (MIGALASTAT HYDROCHLORIDE)
Brand Name : GALAFOLD
Dosage Form : CAPSULE
Dosage Strength : 123MG
Packaging : 14
Approval Date :
Application Number : 2468042
Regulatory Info :
Registration Country : Canada
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Australia
Brand Name : Galafold
Dosage Form :
Dosage Strength :
Packaging : 14
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Migalastat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Migalastat, including repackagers and relabelers. The FDA regulates Migalastat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Migalastat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Migalastat manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Migalastat supplier is an individual or a company that provides Migalastat active pharmaceutical ingredient (API) or Migalastat finished formulations upon request. The Migalastat suppliers may include Migalastat API manufacturers, exporters, distributors and traders.
click here to find a list of Migalastat suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Migalastat DMF (Drug Master File) is a document detailing the whole manufacturing process of Migalastat active pharmaceutical ingredient (API) in detail. Different forms of Migalastat DMFs exist exist since differing nations have different regulations, such as Migalastat USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Migalastat DMF submitted to regulatory agencies in the US is known as a USDMF. Migalastat USDMF includes data on Migalastat's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Migalastat USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Migalastat suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Migalastat Drug Master File in Korea (Migalastat KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Migalastat. The MFDS reviews the Migalastat KDMF as part of the drug registration process and uses the information provided in the Migalastat KDMF to evaluate the safety and efficacy of the drug.
After submitting a Migalastat KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Migalastat API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Migalastat suppliers with KDMF on PharmaCompass.
A Migalastat written confirmation (Migalastat WC) is an official document issued by a regulatory agency to a Migalastat manufacturer, verifying that the manufacturing facility of a Migalastat active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Migalastat APIs or Migalastat finished pharmaceutical products to another nation, regulatory agencies frequently require a Migalastat WC (written confirmation) as part of the regulatory process.
click here to find a list of Migalastat suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Migalastat as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Migalastat API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Migalastat as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Migalastat and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Migalastat NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Migalastat suppliers with NDC on PharmaCompass.
Migalastat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Migalastat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Migalastat GMP manufacturer or Migalastat GMP API supplier for your needs.
A Migalastat CoA (Certificate of Analysis) is a formal document that attests to Migalastat's compliance with Migalastat specifications and serves as a tool for batch-level quality control.
Migalastat CoA mostly includes findings from lab analyses of a specific batch. For each Migalastat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Migalastat may be tested according to a variety of international standards, such as European Pharmacopoeia (Migalastat EP), Migalastat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Migalastat USP).
LOOKING FOR A SUPPLIER?